10 March 2020 - Biofrontera today announced that the European Commission has approved the use of Biofrontera’s prescription drug Ameluz in combination with photodynamic therapy for the treatment of actinic keratosis on the extremities and trunk/neck. 

In addition, the results of the follow-up phase of the clinical study comparing daylight photodynamic therapy with Ameluz and Metvix were included in the product information. With a recurrence rate of 19.5%, Ameluz showed lower recurrence rates after 12 months than Metvix with 31.2%.

Read Biofrontera press release